KASUISTIK

- mortality in leukemia. *Medicine* (Baltimore) 1974; 53:463–78.
6. Callaghan TA, Fitzsimons EJ. Atypical presentation of the hyperleukocytic syndrome: acute myeloid leukaemia with iliac artery occlusion. *Clin Lab Haematol* 1989;11:147–51.
 7. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. *N Engl J Med* 1999;341:1051–62.
 8. Mataix R, Gomez-Casares MT, Campo C, et al. Acute leg ischaemia as a presentation of hyperleukocytosis syndrome in acute myeloid leukaemia. *Am J Hematol* 1996;51:250.
 9. Mauro MJ. Images in clinical medicine. Hyperleukocytosis in acute myeloid leukemia. *N Engl J Med* 2003;349:767.
 10. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. *J Clin Oncol* 1987;5:1364–72.
 11. Majhail NS, Lichtin AE. Acute leukemia with a very high leukocyte count: confronting a medical emergency. *Cleve Clin J Med* 2004;71:633–7.
 12. Novotny JR, Nuckel H, Duhrsen U. Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. *Eur J Haematol* 2006;76: 299–308.
 13. Kalk E, Basu S, Rose P, et al. Acute arterial occlusion as the presenting feature in acute promyelocytic leukaemia. *Br J Haematol* 2001;115:2.
 14. Kootte AM, Thompson J, Bruijn JA. Acute myelocytic leukemia with acute aortic occlusion as presenting symptom. *Acta Haematol* 1986;75:120–1.
 15. Costantini V, Lenti M. Treatment of acute occlusion of peripheral arteries. *Thromb Res* 2002;106: V285–94.
 16. Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleukocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. *Br J Haematol* 1997;98:433–6.
 17. Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. *Leuk Lymphoma* 2000;39:1–18.
 18. Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of venous thromboembolism in patients with acute leukaemia. *Br J Cancer* 2006;94:200–2.
 19. Ziegler S, Sperr WR, Knobl P, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. *Thromb Res* 2005;115:59–64.

*Korrespondenzanschrift**Dr. Jörg Bäsecke**Abteilung Hämatologie und Onkologie**Medizinische Klinik und Poliklinik**Zentrum Innere Medizin**Universität Göttingen**37099 Göttingen**Telefon (+49/551) 396975**Fax -376666**E-Mail: jbaesec@gwdg.de***Erratum**

zu dem Beitrag von
Oliver Witzke, Guido Gerken, Andreas Kribben et al.

Das hepatorenale Syndrom**Wo stehen wir im Jahr 2007?**

Med Klin 2007;102:203–8 (Nr. 3)

DOI 10.1007/s00063-007-1024-5

In der Tabelle 1 und dem entsprechendem Text auf der Seite 204 hätte es unter den Nebenkriterien für die Diagnose des hepatorenalen Syndroms: Urinosmolalität > Plasmaosmolalität (und nicht <) heißen müssen.

Med Klin 2007;102:392.
DOI 10.1007/s00063-007-1051-z